Skip to main content
SpringerLink
Log in

Outcome of treatment of hyperthyroidism

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

This is a retrospective study designed to evaluate the initial response to carbimazole in patients with Graves’ disease (GD), possible determinants of that response, the frequency of occurrence of adverse effects during treatment with carbimazole and the frequency of transient and permanent hypothyroidism after treatment with 131I in patients with GD and multinodular goiter (MNG). Data were collected from patients who first presented with GD or MNG at the Department of Endocrinology of the Royal Infirmary of Edinburgh between 1 January 1993 and 31 August 1996. Patients were divided into three groups: patients with GD treated with a daily dose of 40 mg carbimazole, patients with GD treated with a single dose of 400 MBq 131I, and patients with MNG treated with the same dose of 131I. Of the patients younger than 30 years, 50% remained biochemically hyperthyroid after 4–6 weeks of treatment with carbimazole, compared to 14% of patients over 30. Other determinants of the response to carbimazole expressed as the fall in thyroid hormone levels after 4–6 weeks were: pretreatment levels of FT4, T3, TRAb and the 4 h 131I uptake, patients with the higher levels responding significantly better to carbimazole. Adverse effects were reported in 11.5% of patients. Of the patients with GD treated with 131I, 62.6% became hypothyroid, transient hypothyroidism occurred in only 2.4% of these cases. The main predictors of development of hypothyroidism were positive titres of antithyroid peroxidase antibodies (AbTPO) and antithyroglobulin antibodies (AbTg), with positive predictive values of 79.5 and 91.6 respectively. None of the patients with MNG became hypothyroid after treatment with 131I, a response significantly different from patients with GD. In conclusion, GD younger patients might benefit from higher initial doses of carbimazole. In patients with positive titres of AbTPO and AbTg, lower doses of 131I might prevent hypothyroidism. Transient hypothyroidism was underestimated in this study. No permanent thyroxin replacement therapy should be started within the first six months after 131I treatment. (J. Endocrinol. Invest. 22: 250–256, 1999)

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. De Groot L.J., Larsen P.R., Hennemann G. The thyroid and its diseases. Churchill Livingstone, Edinburg, 1996, 6th edition.

    Google Scholar 

  2. De Bruin T.W.A., Croon C.D.L., De Klerk J.M.H., Van Isselt J.W. Standardized radioiodine therapy in Graves’ disease: the persistent effect of thyroid weight and radioiodine uptake on outcome. J. Int. Med. 1994, 236: 507–513.

    Article  Google Scholar 

  3. Feldt-Rasmussen U., Glinoer D., Orgiazzi J. Reassessment of antithyroid drug therapy of Graves’ disease. Annu. Rev. Med. 1993, 44: 323–334.

    Article  CAS  PubMed  Google Scholar 

  4. Franklyn J.A. The management of hyperthyroidism. New Engl. J. Med. 1994, 30: 1731–1738.

    Google Scholar 

  5. Farrar J.J., Toft A. Iodine-131 treatment of hyperthyroidism: current issues. Clin. Endocrinol. 1991, 35: 207–212.

    Article  CAS  Google Scholar 

  6. Weetman A.P. How anti thyroid drugs work in Graves’ disease. Clin. Endocrinol. 1992, 37: 317–318.

    Article  CAS  Google Scholar 

  7. Braverman L.E. Is there one succesful antithyroid regimen for Graves’ disease? Lancet 1996, 348: 697–698.

    Article  CAS  PubMed  Google Scholar 

  8. Jenkins R.M., Evans D.M.D. Carbimazole hypersensitivity and liver damage. Br. J. Clin. Practice 1981, 35 (11–12): 415–417.

    CAS  Google Scholar 

  9. Peters H., Fisher C., Bogner U., Reiners C., Schleusener H. Radioiodine therapy of Graves’ hyperthyroidism: standard vs calculated 131I iodine activity. Results from a prospective, randomized, multicenter study. Eur. J. Clin. Invest. 1995, 25: 186–193.

    Article  CAS  PubMed  Google Scholar 

  10. Sridama V., McCormick M., Kaplan E.L., Fauchet R., De Groot L.J. Long-term follow-up study of compensated low-dose 131I therapy for Graves’ disease. New Engl. J. Med. 1984, 311 (7) 426–432.

    Article  CAS  PubMed  Google Scholar 

  11. Uy H.L., Reasner C.A., Samuels M.H. Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves’ disease. Am. J. Med. 1995, 99: 173–179.

    Article  CAS  PubMed  Google Scholar 

  12. Toft A. Transient hypothyroidism. Clin. Endocr. 1997, 46: 7–8.

    Article  CAS  PubMed  Google Scholar 

  13. Peters H., Fisher C., Bogner U., Reiners C., Schleusener H. Reduction in thyroid volume after radioiodine therapy of Graves’ hyperthyroidism: results of a prospective, randomized, multicenter study. Eur. J. Clin. Invest. 1996, 26: 59–63.

    Article  CAS  PubMed  Google Scholar 

  14. Benker G., Vitti P., Kahaly G., Raue F., Tegler L., Hirche H., Reinwein D., the European Multicenter Study Group. Response to methimazole in Graves’ disease. Clin. Endocrinol. (Oxf.) 1995, 43: 257–263.

    Article  CAS  Google Scholar 

  15. Yamada T., Aizawa T., Koizumi Y., Komiya I., Ichikawa K., Hashizume K. Age-related therapeutic response to antithyroid drug in patients with hyperthyroid Graves’ disease. J. Am. Geri. Soc. 42 (5) 1994, 513–516.

    CAS  Google Scholar 

  16. Page S.R., Sheard C.E., Herbert M., Hopton M., Jeffcoate W.J. A comparison of 20 or 40 mg per day of carbimazole in the initial treatment of hyperthyroidism. Clin. Endocrinol. (Oxf.) 1996, 45: 511–515.

    Article  CAS  Google Scholar 

  17. Reinwein D., Benker G., Lazarus J.H., Alexander W.D., the European Multicenter Study Group on Antithyroid Drug Treatment. Prospective randomized trial of antithyroid drug dose in Graves’ disease therapy. J. Clin. Endocrinol. Metab. 1993, 76: 1516–1521.

    CAS  PubMed  Google Scholar 

  18. Aizawa Y., Yoshida K., Kaise N., Fukazawa H., Kiso Y., Sayama N., Hori H., Abe K. The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves’ disease: prevalence, mechanism and prognosis. Clin. Endocrinol. (Oxf.) 1996, 46: 1–5.

    Article  Google Scholar 

  19. Gomez N., Gomez J.M., Orti A., Gavalda L., Villabona C., Leyes P., Soler S. Transient hypothyroidism after iodine-131 therapy for Graves’ disease. J. Nucl. Med. 1995, 36: 1539–1542.

    CAS  PubMed  Google Scholar 

  20. Lindsay R.S., Toft A.D. Hypothyroidism. Lancet 1997, 349: 413–417.

    Article  CAS  PubMed  Google Scholar 

  21. Franklyn J.A., Daykin J., Holder R., Sheppard M.C. Radioiodine therapy compared in patients with toxic nodular or Graves’ hyperthyroidism. Q. J. Med. 1995, 88: 175–180.

    CAS  Google Scholar 

  22. Berg G., Michanek A., Holmberg E., Nystrom E. Clinical outcome of radioiodine treatment of hyperthyroidism: a follow up study. J. Int. Med. 1996, 239: 165–171.

    Article  CAS  Google Scholar 

  23. Sawers J.S.A., Toft A.D., Irvine W.J., Brown N.S., Seth J. Transient hypothyroidism after iodine-131 treatment of thyrotoxicosis. J. Clin. Endocrinol. Metab. 1980, 50: 226–229;.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University Hospital Rotterdam, Tamboerstraat 16a, 3034 PV, Rotterdam, The Netherlands

    I. M. Bringmann M.D., B. L. van Leeuwen & G. Hennemann

  2. Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, Edinburgh, Great Britain

    G. J. Beckett

  3. Department of Endocrinology, Royal Infirmary of Edinburgh, Edinburgh, Great Britain

    A. D. Toft

Authors
  1. I. M. Bringmann M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. L. van Leeuwen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Hennemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. J. Beckett
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. D. Toft
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bringmann, I.M., van Leeuwen, B.L., Hennemann, G. et al. Outcome of treatment of hyperthyroidism. J Endocrinol Invest 22, 250–256 (1999). https://doi.org/10.1007/BF03343552

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03343552

Key-words

Search

Navigation